Table 1 Summary of clinical attributes and PD-L1 Expression in SCLC
From: Tumor and host characteristics of small cell lung cancer (SCLC) in U.S. community oncology practice
Characteristic | Cohort | PD-L1 (<1%) | PD-L1 (≥1%) | Frequency in PD-L1 ≥1% | Fisher (pV) |
|---|---|---|---|---|---|
Smoking status | EVER | 70 | 13 | 15.7% | Â |
| Â | NEVER | 4 | 0 | 0.0% | 1.00 |
Sex | Male | 40 | 6 | 13.0% | Â |
| Â | Female | 34 | 7 | 17.1% | 0.765 |
ECOG | 0-1 | 49 | 7 | 12.5% | Â |
| Â | 2-3 | 21 | 6 | 22.2% | 0.335 |
Age | <70 | 47 | 5 | 10% | Â |
|  | ≥70 | 27 | 8 | 23% | 0.126 |
Autoimmune Disorders | Present | 4 | 3 | 42.9% | Â |
| Â | Absent | 68 | 9 | 11.7% | 0.057 |
Site of biopsy for PDL1 samples* | Primary | 37 | 6 | 14.0% | Â |
| Â | Metastatic | 36 | 7 | 16.3% | Â |
| Â | Primary/Metastatic | 1 | 0 | 0.0% | 1.000 |
H&E – Tumor Tissue Inflammation* | Absent | 20 | 2 | 9.1% |  |
| Â | Present | 30 | 6 | 16.7% | 0.6971 |
H&E – Tumor Tissue Necrosis | Absent | 31 | 3 | 8.8% |  |
| Â | Present | 19 | 5 | 20.8% | 0.2254 |
H&E-% Intra-Tumoral Inflammatory Infiltrate* | <10% | 41 | 1 | 2.4% | Â |
|  | ≥10% | 30 | 10 | 33.3% | 0.003 |